SE548109C2 - Microglial endocytic receptors for use in the treatment of neurodegenerative disease - Google Patents

Microglial endocytic receptors for use in the treatment of neurodegenerative disease

Info

Publication number
SE548109C2
SE548109C2 SE2350348A SE2350348A SE548109C2 SE 548109 C2 SE548109 C2 SE 548109C2 SE 2350348 A SE2350348 A SE 2350348A SE 2350348 A SE2350348 A SE 2350348A SE 548109 C2 SE548109 C2 SE 548109C2
Authority
SE
Sweden
Prior art keywords
microglial
treatment
neurodegenerative disease
endocytic receptors
endocytic
Prior art date
Application number
SE2350348A
Other versions
SE2350348A1 (en
Inventor
Andreas Björefeldt
Rebecca Riise
John Henrik Zetterberg
Eric Hanse
Original Assignee
Cerimmune Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerimmune Therapeutics Ab filed Critical Cerimmune Therapeutics Ab
Priority to SE2350348A priority Critical patent/SE548109C2/en
Priority to EP24718708.1A priority patent/EP4688821A1/en
Priority to PCT/EP2024/058078 priority patent/WO2024200420A1/en
Publication of SE2350348A1 publication Critical patent/SE2350348A1/en
Publication of SE548109C2 publication Critical patent/SE548109C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE2350348A 2023-03-28 2023-03-28 Microglial endocytic receptors for use in the treatment of neurodegenerative disease SE548109C2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE2350348A SE548109C2 (en) 2023-03-28 2023-03-28 Microglial endocytic receptors for use in the treatment of neurodegenerative disease
EP24718708.1A EP4688821A1 (en) 2023-03-28 2024-03-26 Microglial endocytic receptors for use in the treatment of neurodegenerative disease
PCT/EP2024/058078 WO2024200420A1 (en) 2023-03-28 2024-03-26 Microglial endocytic receptors for use in the treatment of neurodegenerative disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE2350348A SE548109C2 (en) 2023-03-28 2023-03-28 Microglial endocytic receptors for use in the treatment of neurodegenerative disease

Publications (2)

Publication Number Publication Date
SE2350348A1 SE2350348A1 (en) 2024-09-29
SE548109C2 true SE548109C2 (en) 2026-03-30

Family

ID=90730383

Family Applications (1)

Application Number Title Priority Date Filing Date
SE2350348A SE548109C2 (en) 2023-03-28 2023-03-28 Microglial endocytic receptors for use in the treatment of neurodegenerative disease

Country Status (3)

Country Link
EP (1) EP4688821A1 (en)
SE (1) SE548109C2 (en)
WO (1) WO2024200420A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015480A2 (en) * 2006-08-01 2008-02-07 Immunobiology Limited Composition and method for modulating an immune response
US20190233496A1 (en) * 2016-03-23 2019-08-01 Alector Llc Chimeric receptors and methods of use thereof
WO2019157440A1 (en) * 2018-02-09 2019-08-15 The Trustees Of Dartmouth College Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders
WO2019191332A1 (en) * 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
WO2021146620A2 (en) * 2020-01-17 2021-07-22 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
WO2022161502A1 (en) * 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 Targeted protein degradation system and use thereof
WO2022178367A2 (en) * 2021-02-19 2022-08-25 University Of Southern California Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
WO2022197974A1 (en) * 2021-03-18 2022-09-22 University Of Florida Research Foundation, Incorporated Chimeric phagocytic receptors for treatment of neurodegenerative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
EP4089116A1 (en) * 2016-09-27 2022-11-16 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015480A2 (en) * 2006-08-01 2008-02-07 Immunobiology Limited Composition and method for modulating an immune response
US20190233496A1 (en) * 2016-03-23 2019-08-01 Alector Llc Chimeric receptors and methods of use thereof
WO2019157440A1 (en) * 2018-02-09 2019-08-15 The Trustees Of Dartmouth College Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders
WO2019191332A1 (en) * 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
WO2021146620A2 (en) * 2020-01-17 2021-07-22 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
WO2022161502A1 (en) * 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 Targeted protein degradation system and use thereof
WO2022178367A2 (en) * 2021-02-19 2022-08-25 University Of Southern California Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
WO2022197974A1 (en) * 2021-03-18 2022-09-22 University Of Florida Research Foundation, Incorporated Chimeric phagocytic receptors for treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
WO2024200420A1 (en) 2024-10-03
EP4688821A1 (en) 2026-02-11
SE2350348A1 (en) 2024-09-29

Similar Documents

Publication Publication Date Title
GB2595776B (en) Therapeutic solid dosage forms
EP3954395A4 (en) Pharmaceutical composition for muscle disease treatment
IL217901B (en) Use of an amount of laquninimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a human subject suffering from a bdnf-related disease
IL195135A0 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
GB202103211D0 (en) Pharmaceutical compounds for use in therapy
SMT202400271T1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease
IL326136A (en) Rmc-6291 for use in the treatment of ras protein-related disease or disorder
JP2019535799A5 (en)
GB202109707D0 (en) Adjustable therapeutic scoliosis brace
SE548109C2 (en) Microglial endocytic receptors for use in the treatment of neurodegenerative disease
GB202016425D0 (en) Treatment regimens for parkinson's disease
ZA202209478B (en) Rat fixator for cheek acupuncture
GB202210731D0 (en) Therapeutic agents
SMT202500307T1 (en) 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases
PL4072532T3 (en) Dosage form for use in the treatment or prevention of a disease
EP3752614A4 (en) OLIGONUCLEOTID THERAPY FOR WILSON'S DISEASE
HRP20251502T1 (en) CONTINUOUS USE OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF NEURODEGENERATE DISORDERS
EP3439640A4 (en) NANOPARTICLES FOR DRUG ADMINISTRATION FOR TREATING BONE DISEASE
GB202218846D0 (en) Therapeutic agents
EP3470091A4 (en) NON-INVASIVE DIAGNOSTIC IMAGING AGENT FOR CARDIAC DISEASE
IL267716A (en) Drug combination treatments using bone-targeting therapeutics for bone and bone-related disease
EP4125939A4 (en) Inhaled xenon therapy in neurodegenerative disease
EP3791888A4 (en) THERAPEUTIC AGENT FOR SPINAL CORD INJURY
IL271795A (en) Screening platform to identify therapeutic drugs or agents for treatment of alzheimer's disease
GB202414668D0 (en) Ultrasound-responsive nanoscale delivery platform for use in the treatment of biofilm-associated diseases